An analysis of data from 24 Italian MS centres has identified factors associated with an early change of disease-modifying therapy (Sacca et al. Mult Scler 2018; epublished July 25, 2018). Read More
Latest News
Inhibiting CGRP in migraine prophylaxis
July 25, 2018SPECIAL REPORT
60th Annual Scientific Meeting of the American Headache Society, San Francisco CA, 29 June – 1 July 2018 – Erenumab, the first in a new class of monoclonal antibodies that inhibit calcitonin gene-related peptide (CGRP), has now been approved in the U.S. Other agents in development are fremanezumab, eptinezumab and galcanezumab. The following is a summary of new data on these agents presented at the 60th annual meeting of the American Headache Society. Read More
Emerging approach to improve functional recovery post-stroke
July 18, 2018A large database analysis has reported that histone deacetylase (HDAC) inhibition may be beneficial in the secondary prevention of ischemic stroke (Brookes et al. Stroke 2018;49:54-61). Read More
Exploring therapeutic inertia in multiple sclerosis
July 11, 2018SPECIAL REPORT
Comment by Dr. Daniel Selchen – St. Michael’s Hospital, Toronto, Ontario
An estimated 70% of clinicians managing multiple sclerosis experience therapeutic inertia when faced with the decision to escalate therapy, according to a series of studies conducted by Saposnik and colleagues. This delay in the use of more effective therapies may result in worse clinical outcomes. Read More